Alzheimer s & Dementia · 2020 · 54 citations · 29 references
Life SciencesGeneticsNeurologyDementiaMedical GeneticsNeurodegenerationAlzheimer DiseaseDementia GeneticsDementia Risk FactorsNeurodegenerative Disease GeneticsNeurodegenerative DiseasesNeurodegenerative DisordersAlzheimer Disease RiskApolipoprotein E Genotype RiskApp MutationsControlsFamilial DementiaGenetic Risk MarkersPsen1 MutationsPsen2 Mutations
INTRODUCTION: The genetic risk effects of apolipoprotein E (APOE) on familial Alzheimer's disease (FAD) with or without gene mutations, sporadic AD (SAD), and normal controls (NC) remain unclear in the Chinese population. METHODS: In total, 15 119 subjects, including 311 FAD patients without PSEN1, PSEN2, APP, TREM2, and SORL1 pathogenic mutations (FAD [unknown]); 126 FAD patients with PSENs/APP mutations (FAD [PSENs/APP]); 7234 SAD patients; and 7448 NC were enrolled. The risk effects of APOE ε4 were analyzed across groups. RESULTS: The prevalence of the APOE ε4 genotype in FAD (unknown), FAD (PSENs/APP), SAD, and NC groups was 56.27%, 26.19%, 36.23%, and 19.54%, respectively. Further, the APOE ε4 positive genotype had predictive power for FAD (unknown) risk (odds ratio: 4.51, 95% confidence interval: 3.57-5.45, P < .001). DISCUSSION: APOE ε4 positive genotype may cause familial aggregation, and the investigation of multiple interventions targeting APOE pathological function to reduce the risk for this disease warrants attention.
29
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Guy M. McKhann, David S. Knopman, Howard Chertkow et al. · Alzheimer s & Dementia · 2011 · 18.8K citations · Full text